Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity.

Abstract:

:Identification of agents that target human leukemia stem cells is an important consideration for the development of new therapies. The present study demonstrates that rocaglamide and silvestrol, closely related natural products from the flavagline class of compounds, are able to preferentially kill functionally defined leukemia stem cells, while sparing normal stem and progenitor cells. In addition to efficacy as single agents, flavaglines sensitize leukemia cells to several anticancer compounds, including front-line chemotherapeutic drugs used to treat leukemia patients. Mechanistic studies indicate that flavaglines strongly inhibit protein synthesis, leading to the reduction of short-lived antiapoptotic proteins. Notably though, treatment with flavaglines, alone or in combination with other drugs, yields a much stronger cytotoxic activity toward leukemia cells than the translational inhibitor temsirolimus. These results indicate that the underlying cell death mechanism of flavaglines is more complex than simply inhibiting general protein translation. Global gene expression profiling and cell biological assays identified Myc inhibition and the disruption of mitochondrial integrity to be features of flavaglines, which we propose contribute to their efficacy in targeting leukemia cells. Taken together, these findings indicate that rocaglamide and silvestrol are distinct from clinically available translational inhibitors and represent promising candidates for the treatment of leukemia.

journal_name

Leukemia

journal_title

Leukemia

authors

Callahan KP,Minhajuddin M,Corbett C,Lagadinou ED,Rossi RM,Grose V,Balys MM,Pan L,Jacob S,Frontier A,Grever MR,Lucas DM,Kinghorn AD,Liesveld JL,Becker MW,Jordan CT

doi

10.1038/leu.2014.93

subject

Has Abstract

pub_date

2014-10-01 00:00:00

pages

1960-8

issue

10

eissn

0887-6924

issn

1476-5551

pii

leu201493

journal_volume

28

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.

    abstract::Vascular endothelial growth factor (VEGF) and its receptors (VEGFR) have been implicated in promoting solid tumor growth and metastasis via stimulating tumor-associated angiogenesis. We recently showed that certain 'liquid' tumors such as leukemia not only produce VEGF, but also express functional VEGFR, resulting in ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402831

    authors: Zhu Z,Hattori K,Zhang H,Jimenez X,Ludwig DL,Dias S,Kussie P,Koo H,Kim HJ,Lu D,Liu M,Tejada R,Friedrich M,Bohlen P,Witte L,Rafii S

    更新日期:2003-03-01 00:00:00

  • Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.

    abstract::Because of their substantial in vitro synergy, we conducted a dose-escalation study of cyclophosphamide (CP) added to 2-chloro-2'-deoxyadenosine (CdA) in patients with previously treated chronic lymphocytic leukemia and non-Hodgkin's lymphoma. CdA was given at a fixed dose (5.6 mg/m2/day) as a 2-h intravenous (i.v.) i...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.leu.2401783

    authors: Van Den Neste E,Louviaux I,Michaux JL,Delannoy A,Michaux L,Sonet A,Bosly A,Doyen C,Mineur P,André M,Straetmans N,Coche E,Venet C,Duprez T,Ferrant A

    更新日期:2000-06-01 00:00:00

  • Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive and -negative diffuse large B cell lymphoma.

    abstract::We analyzed nucleotide sequence and intraclonal diversity of the rearranged immunoglobulin heavy chain gene variable region (VH gene) of CD5+ and CD5- diffuse large B cell lymphoma (DLBCL) to clarify the cell origin of de novo CD5+ DLBCL. Ten cases of CD5+ DLBCL and 29 cases of CD5- DLBCL were analyzed. The frequencie...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402031

    authors: Nakamura N,Kuze T,Hashimoto Y,Hara Y,Hoshi S,Sasaki Y,Shirakawa A,Sato M,Abe M

    更新日期:2001-03-01 00:00:00

  • LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.

    abstract::LSD1 has emerged as a promising epigenetic target in the treatment of acute myeloid leukemia (AML). We used two murine AML models based on retroviral overexpression of Hoxa9/Meis1 (H9M) or MN1 to study LSD1 loss of function in AML. The conditional knockout of Lsd1 resulted in differentiation with both granulocytic and...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0375-7

    authors: Barth J,Abou-El-Ardat K,Dalic D,Kurrle N,Maier AM,Mohr S,Schütte J,Vassen L,Greve G,Schulz-Fincke J,Schmitt M,Tosic M,Metzger E,Bug G,Khandanpour C,Wagner SA,Lübbert M,Jung M,Serve H,Schüle R,Berg T

    更新日期:2019-06-01 00:00:00

  • MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.

    abstract::MK-0457, an Aurora kinase and BCR-ABL inhibitor, was studied on a Phase I/II study in 77 patients with refractory hematologic malignancies. The average number of cycles per patient was 3 (range 1-21). Maximum tolerated doses for a 5-day short infusion and continuous infusion regimens were 40 mg/m(2)/h and 144 mg/m(2)/...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.186

    authors: Giles FJ,Swords RT,Nagler A,Hochhaus A,Ottmann OG,Rizzieri DA,Talpaz M,Clark J,Watson P,Xiao A,Zhao B,Bergstrom D,Le Coutre PD,Freedman SJ,Cortes JE

    更新日期:2013-01-01 00:00:00

  • Distribution of IL-6 receptors on murine hemopoietic and lymphoid cells and the anomalous action of IL-6 in stimulating granulocytic proliferation.

    abstract::Autoradiographic analysis of the binding of radiolabeled murine IL-6 to murine cells revealed that blast cells, megakaryocytic and monocytic cells in the marrow expressed receptors but not erythroid, eosinophilic or neutrophilic granulocytic cells. In the thymus, spleen and lymph nodes, most cells expressing receptors...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: McKinstry W,Metcalf D,Li CL

    更新日期:1994-10-01 00:00:00

  • Identification of CD34+ cells in normal and pathological bone marrow biopsies by QBEND10 monoclonal antibody.

    abstract::Monoclonal antibody QBEND10 is reactive with the CD34 antigen in aldehyde-fixed, decalcified, paraffin-embedded bone marrow biopsies. In normal bone marrow it stained endothelial cells lining arterioles and capillaries, sinusoidal (littoral) cells and 0.89% of all haemopoietic cells. QBEND10+ mononuclear cells were se...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Soligo D,Delia D,Oriani A,Cattoretti G,Orazi A,Bertolli V,Quirici N,Deliliers GL

    更新日期:1991-12-01 00:00:00

  • Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60).

    abstract::The p21MDA6 gene product induces cell cycle arrest in p53-null human leukemic cells exposed to differentiation stimuli. We employed an HL-60 cell line stably transfected with a p21MDA6 antisense construct to compare the effects of p21MDA6 dysregulation on the response of myeloid leukemia cells to differentiating and c...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400625

    authors: Freemerman AJ,Vrana JA,Tombes RM,Jiang H,Chellappan SP,Fisher PB,Grant S

    更新日期:1997-04-01 00:00:00

  • Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.

    abstract::ADMIRE was a multicenter, randomized-controlled, open, phase IIB superiority trial in previously untreated chronic lymphocytic leukemia. Conventional front-line therapy in fit patients is fludarabine, cyclophosphamide and rituximab (FCR). Initial evidence from non-randomized phase II trials suggested that the addition...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/leu.2017.65

    authors: Munir T,Howard DR,McParland L,Pocock C,Rawstron AC,Hockaday A,Varghese A,Hamblin M,Bloor A,Pettitt A,Fegan C,Blundell J,Gribben JG,Phillips D,Hillmen P

    更新日期:2017-10-01 00:00:00

  • Modulation of cell surface protein expression by infection with HIV-1.

    abstract::The examples discussed above show the profound influence of HIV infection on expression pattern of cell surface proteins and the functional relevance thereof. Altered cell surface pattern is involved in all aspects of HIV-induced pathogenesis such as viral spreading viral adhesion and cellular apoptosis and is an impo...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2401322

    authors: Speth C,Dierich MP

    更新日期:1999-04-01 00:00:00

  • Characterisation of non-concordance in the T-cell receptor gamma chain genes at presentation and clinical relapse in acute lymphoblastic leukemia.

    abstract::We have analysed the structure of the T-cell receptor gamma chain (TCRG) genes in a panel of biopsies taken from 24 patients with acute lymphoblastic leukemia (ALL) (13 cALL, one pre-B ALL, two null ALL and eight T-ALL) at presentation and at clinical relapse. In the majority of cases (18/24) the structure of these ge...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Taylor JJ,Rowe D,Kylefjord H,Chessells J,Katz F,Proctor SJ,Middleton PG

    更新日期:1994-01-01 00:00:00

  • Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.

    abstract::The long-term results in 130 patients with newly diagnosed acute myelogenous leukemia treated with continuous infusion high-dose ara-C (1.5 gm/m2/day x 4 days, CIHDAC) were compared with those in 264 patients treated in previous studies with standard dose ara-C (70-90 mg/m2/d x 7 days) plus either adriamycin (Ad-OAP),...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:

    authors: Ghaddar HM,Plunkett W,Kantarjian HM,Pierce S,Freireich EJ,Keating MJ,Estey EH

    更新日期:1994-08-01 00:00:00

  • To be or not to be a T-lymphomas, that is determined by a dominant gene Tlsm-1 in mouse models.

    abstract::A single dominant gene Tlsm-1 was found to determine the type of spontaneous lymphomas to be T in the cross between AKR/Ms and SL/Kh. Microsatellite analysis mapped Tlsm-1 at the position 61 cM from centromere of Chr. 7. Study of this segment of T-lymphoma prone AKXD Rl strains also showed association of Tlsm-1 with T...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Hiai H,Yamada Y,Shisa H,Kamoto T,Abujiang P,Lu LM

    更新日期:1997-04-01 00:00:00

  • Facilitated engraftment of human hematopoietic cells in severe combined immunodeficient mice following a single injection of Cl2MDP liposomes.

    abstract::Transplantation of normal and malignant human hematopoietic cells into severe combined immunodeficient (SCID) mice allows for evaluation of long-term growth abilities of these cells and provides a preclinical model for therapeutic interventions. However, large numbers of cells are required for successful engraftment i...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400694

    authors: Terpstra W,Leenen PJ,van den Bos C,Prins A,Loenen WA,Verstegen MM,van Wyngaardt S,van Rooijen N,Wognum AW,Wagemaker G,Wielenga JJ,Löwenberg B

    更新日期:1997-07-01 00:00:00

  • Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease.

    abstract::We compared blast cells from adult and pediatric patients with untreated acute lymphoblastic leukemia (ALL) (as separated groups of T-lineage cell and B-lineage cell ALL) to determine if methotrexate (MTX) polyglutamate formation in adult patients might be a contributing cause to the known difference in clinical outco...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Göker E,Lin JT,Trippett T,Elisseyeff Y,Tong WP,Niedzwiecki D,Tan C,Steinherz P,Schweitzer BI,Bertino JR

    更新日期:1993-07-01 00:00:00

  • The role of TGFβ in hematopoiesis and myeloid disorders.

    abstract::The role of transforming growth factor-β (TGFβ) signaling in embryological development and tissue homeostasis has been thoroughly characterized. Its canonical downstream cascade is well known, even though its true complexity and other non-canonical pathways are still being explored. TGFβ signaling has been described a...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-019-0420-1

    authors: Bataller A,Montalban-Bravo G,Soltysiak KA,Garcia-Manero G

    更新日期:2019-05-01 00:00:00

  • Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report.

    abstract::Infants <1 year of age have a high prevalence of prognostically unfavorable leukemias and a presumed susceptibility to treatment-related toxicities. A total of 125 infants with acute myeloid leukemia (AML) were treated in studies AML-BFM-98 (n = 59) and -2004 (n = 66). Treatment regimens of both studies were comparabl...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.267

    authors: Creutzig U,Zimmermann M,Bourquin JP,Dworzak MN,Kremens B,Lehrnbecher T,von Neuhoff C,Sander A,von Stackelberg A,Schmid I,Starý J,Steinbach D,Vormoor J,Reinhardt D

    更新日期:2012-04-01 00:00:00

  • Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.

    abstract::Transformation of post-myeloproliferative neoplasms into secondary (s) AML exhibit poor clinical outcome. In addition to increased JAK-STAT and PI3K-AKT signaling, post-MPN sAML blast progenitor cells (BPCs) demonstrate increased nuclear β-catenin levels and TCF7L2 (TCF4) transcriptional activity. Knockdown of β-caten...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0334-3

    authors: Saenz DT,Fiskus W,Manshouri T,Mill CP,Qian Y,Raina K,Rajapakshe K,Coarfa C,Soldi R,Bose P,Borthakur G,Kadia TM,Khoury JD,Masarova L,Nowak AJ,Sun B,Saenz DN,Kornblau SM,Horrigan S,Sharma S,Qiu P,Crews CM,Versto

    更新日期:2019-06-01 00:00:00

  • Deficiency of a phosphatidylinositol-anchored cell adhesion molecule influences haemopoietic progenitor binding to marrow stroma in chronic myeloid leukaemia.

    abstract::The interactions between haemopoietic progenitor cells and marrow stromal cells that are essential for the regulation of normal haemopoiesis are defective in chronic phase chronic myeloid leukaemia (CML). The presence of primitive progenitor cells (blast colony-forming cells, Bl-CFC) in the blood of patients with CML ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Gordon MY,Atkinson J,Clarke D,Dowding CR,Goldman JM,Grimsley PG,Siczkowski M,Greaves MF

    更新日期:1991-08-01 00:00:00

  • Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.

    abstract::JAK2V617F is the most common mutation in patients with BCR-ABL negative myeloproliferative neoplasms (MPNs). The eradication of JAK2V617F hematopoietic stem cells (HSCs) is critical for achieving molecular remissions and cure. We investigate the distinct effects of two therapies, ruxolitinib (JAK1/2 inhibitor) and int...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0638-y

    authors: Austin RJ,Straube J,Bruedigam C,Pali G,Jacquelin S,Vu T,Green J,Gräsel J,Lansink L,Cooper L,Lee SJ,Chen NT,Lee CW,Haque A,Heidel FH,D'Andrea R,Hill GR,Mullally A,Milsom MD,Bywater M,Lane SW

    更新日期:2020-04-01 00:00:00

  • CD44 isoforms distinguish between bone marrow plasma cells from normal individuals and patients with multiple myeloma at different stages of disease.

    abstract::CD44 variant isoforms (CD44v) have been shown to be important factors in adverse prognosis in hematological malignancies. To investigate whether CD44 expression is associated with malignant transformation in multiple myeloma, RNA and protein expression of CD44 standard (CD44s) and CD44v4, v6, v9, v10 containing isofor...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401179

    authors: van Driel M,Günthert U,Stauder R,Joling P,Lokhorst HM,Bloem AC

    更新日期:1998-11-01 00:00:00

  • Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.

    abstract::We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-alpha failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402996

    authors: Marin D,Marktel S,Bua M,Szydlo RM,Franceschino A,Nathan I,Foot N,Crawley C,Na Nakorn T,Olavarria E,Lennard A,Neylon A,O'Brien SG,Goldman JM,Apperley JF

    更新日期:2003-08-01 00:00:00

  • Stimulation of leukemic myelopoiesis by P30-35 CAMAL, an inhibitor of normal myelopoiesis.

    abstract::CAMAL (common antigen in myelogenous acute leukemia) is an antigenic preparation isolated in this laboratory from the bone marrow or peripheral blood cells of persons with myeloid leukemias and shown in an immunoperoxidase slide test to be diagnostic of these leukemias. CAMAL has been shown to be inhibitory to myelopo...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Leitch HA,Buskard N,Levy JG

    更新日期:1993-09-01 00:00:00

  • CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia.

    abstract::Employing a multicolour flow cytometry assay, 133 B-chronic lymphocytic leukaemia (B-CLL) cases were analysed for surface expression of CD38. Based on a cut-off value of 20%, CLL patients were categorised into a CD38-positive (> or = 20%, n = 56) and a CD38-negative subgroup (< 20%, n = 77) and separately analysed for...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402339

    authors: Dürig J,Naschar M,Schmücker U,Renzing-Köhler K,Hölter T,Hüttmann A,Dührsen U

    更新日期:2002-01-01 00:00:00

  • Disruption of the BCL11B gene through inv(14)(q11.2q32.31) results in the expression of BCL11B-TRDC fusion transcripts and is associated with the absence of wild-type BCL11B transcripts in T-ALL.

    abstract::T-cell acute lymphoblastic leukemia (T-ALL) is associated with chromosomal aberrations characterized by juxtaposition of proto-oncogenes to T-cell receptor gene loci (TCR), resulting in the deregulated transcription of these proto-oncogenes. Here, we describe the molecular characterization of a novel chromosomal aberr...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403619

    authors: Przybylski GK,Dik WA,Wanzeck J,Grabarczyk P,Majunke S,Martin-Subero JI,Siebert R,Dölken G,Ludwig WD,Verhaaf B,van Dongen JJ,Schmidt CA,Langerak AW

    更新日期:2005-02-01 00:00:00

  • Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias.

    abstract::Activating mutations in NOTCH1 are found in over 50% of human T-cell lymphoblastic leukemias (T-ALLs). Here, we report the analysis for activating NOTCH1 mutations in a large number of acute myeloid leukemia (AML) primary samples and cell lines. We found activating mutations in NOTCH1 in a single M0 primary AML sample...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404409

    authors: Palomero T,McKenna K,O-Neil J,Galinsky I,Stone R,Suzukawa K,Stiakaki E,Kalmanti M,Fox EA,Caligiuri MA,Aster JC,Look AT,Ferrando AA

    更新日期:2006-11-01 00:00:00

  • A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes.

    abstract::The use of darbepoetin alfa to treat anemia in patients with lower-risk myelodysplastic syndromes (MDS) was evaluated in a phase 3 trial. Eligible patients had low/intermediate-1 risk MDS, hemoglobin ⩽10 g/dl, low transfusion burden and serum erythropoietin (EPO) ⩽500 mU/ml. Patients were randomized 2:1 to receive 24 ...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/leu.2017.192

    authors: Platzbecker U,Symeonidis A,Oliva EN,Goede JS,Delforge M,Mayer J,Slama B,Badre S,Gasal E,Mehta B,Franklin J

    更新日期:2017-09-01 00:00:00

  • The effects of combinations of the recombinant growth factors GM-CSF, G-CSF, IL-3, and CSF-1 on leukemic blast cells in suspension culture.

    abstract::The blast cells of acute myeloblastic leukemia may be considered as a renewal population maintained by stem cells that are capable of both self-renewal and differentiation. Blast stem cells grow in culture usually when stimulated by growth factors normally active on myelopoietic cells. Two culture methods permit an ev...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Miyauchi J,Kelleher CA,Wong GG,Yang YC,Clark SC,Minkin S,Minden MD,McCulloch EA

    更新日期:1988-06-01 00:00:00

  • Amplification and sequencing of genomic breakpoints located within the M-bcr region by Vectorette-mediated polymerase chain reaction.

    abstract::The polymerase chain reaction (PCR) cannot be used to amplify the breakpoint in the chimaeric BCR-ABL gene in CML and acute leukaemias due to the large variation in the sites of breakpoint in the BCR gene (within a 5.8 kb region) and in the ABL gene (within a 150 kb region). The disease state is usually monitored usin...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Mills KI,Sproul AM,Ogilvie D,Elvin P,Leibowitz D,Burnett AK

    更新日期:1992-05-01 00:00:00

  • Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients.

    abstract::The main reason for the unfavorable clinical outcome of BCR-ABL1-positive acute lymphoblastic leukemia (ALL) is genetic instability. However, how normal B-cell precursors acquire the genetic changes that lead to transformation has not yet been completely defined. We investigated the expression of the activation-induce...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2009.197

    authors: Iacobucci I,Lonetti A,Messa F,Ferrari A,Cilloni D,Soverini S,Paoloni F,Arruga F,Ottaviani E,Chiaretti S,Messina M,Vignetti M,Papayannidis C,Vitale A,Pane F,Piccaluga PP,Paolini S,Berton G,Baruzzi A,Saglio G,Baccar

    更新日期:2010-01-01 00:00:00